Drug intelligence / Profile preview

Pep(4)

Development stage: Preclinical
Lead developer: University of Gdańsk
Modality: Peptides

Overview

Pep(4) is a synthetic peptide derived from the Herpes Simplex Virus (HSV) glycoprotein D (gD), specifically representing the 1-17 amino acid sequence of the protein. It functions as an immune checkpoint inhibitor by targeting the Herpesvirus Entry Mediator (HVEM), also known as TNFRSF14. Pep(4) is designed to competitively inhibit the binding of B- and T-lymphocyte attenuator (BTLA) to HVEM. By disrupting the BTLA-HVEM inhibitory complex, Pep(4) aims to restore and enhance T-cell mediated immune responses against tumors. Research has primarily focused on its potential application in melanoma, where it has demonstrated the ability to modulate cytokine production and T-cell activation in patient-derived samples.

Other names: gD(1-17)gD-derived peptide 4

Targets

TMEFF2

Beyond the preview

Go deeper on Pep(4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pep(4).

Explore the full profile